OncoSwab
OncoSwab offers a non-invasive nasal swab-based test for early lung cancer detection. Their technology utilizes cellular markers from nasal fluids, analyzed by machine learning algorithms, to provide accurate risk assessment, thereby reducing the need for invasive procedures and improving patient comfort and compliance. The company is actively undergoing multi-center clinical validation across more than 10 hospitals in Europe and the US. Initially focused on lung cancer, OncoSwab's platform is designed for expansion into other respiratory diseases. Their business model appears to be centered around providing a diagnostic service, potentially with licensing or partnership opportunities for broader healthcare integration.
OncoSwab
OncoSwab offers a non-invasive nasal swab-based test for early lung cancer detection. Their technology utilizes cellular markers from nasal fluids, analyzed by machine learning algorithms, to provide accurate risk assessment, thereby reducing the need for invasive procedures and improving patient comfort and compliance. The company is actively undergoing multi-center clinical validation across more than 10 hospitals in Europe and the US. Initially focused on lung cancer, OncoSwab's platform is designed for expansion into other respiratory diseases. Their business model appears to be centered around providing a diagnostic service, potentially with licensing or partnership opportunities for broader healthcare integration.